Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine ...( PLYMOUTH MEETING Pa. Sept. 10 /- ...),Health

PLYMOUTH MEETING, Pa., Sept. 10 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced the formation of its Trodusquemine Scientific Advisory Board (the "SAB"), consisting of leading experts in the areas of obesity, diabetes and metabolic disorders, to provide guidance on the development of trodusquemine (MSI-1436), the Company's novel small molecule drug candidate for the treatment of obesity and type 2 diabetes.

"Genaera is privileged and honored to work with this prestigious group of nationally and internationally recognized experts to guide our MSI-1436 clinical development," commented Jack Armstrong, President and CEO of Genaera. "The expertise of this advisory board is a valuable resource to help ensure Genaera adopts the most scientifically focused and clinically effective development plan as we move forward with this unique therapeutic agent."

"With more than 60 million Americans classified as obese, there is a critical need for innovative therapies to manage metabolic disorders," noted Dr. Thomas Wadden, Professor of Psychology and Director of the Center for Weight Loss and Eating Disorders at the University of Pennsylvania. "I am pleased to serve on Genaera's SAB to provide direction on the current and future development of this therapeutic agent for the treatment of both obesity and type 2 diabetes."

"Despite recent advances, obesity and diabetes remain major global health issues," stated Dr. Louis Aronne, Clinical Professor of Medicine at the Weill Cornell Medical College. "Targeting these areas for future clinical research will have a major public health impact. Although early in development, trodusquemine is among the promising therapies in development for the trea
'/>"/>